Clicky

Tikcro Technologies(TIKRF)

Description: Tikcro Technologies Ltd. (Tikcro) provides funding for early-stage biotechnology projects with a focus on oncology. The Company provides funding for early-stage biotechnology projects originating in Israeli academic centers. The Company's product candidate antibodies focuses on blocking the ligand/receptor linkage of certain biological pathways, specifically antibodies that block anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed cell death protein 1 (PD-1), and by blocking these pathways to prevent the inhibition of patients' self immune system and its ability to attack cancerous cells. The Company focuses on antibody drug-candidates that block the binding surface domain and do not block adjacent domains. The Company's project focuses on the immune system pathways, which include CTLA-4 and its binding group of ligands; PD-1 and ligands PDL-1 and PDL-2, and T cell immunoreceptor with Ig and ITIM domains (TIGIT) and its binding group of ligands.


Keywords: Medicine Biotechnology Immunology Antibodies Immune System Cancer Immunotherapy Antibody T Cell Immune Checkpoint Programmed Cell Death Protein 1 Technology Projects Programmed Cell Death Attack Cancer Lymphocyte Cell Death Tigit

Home Page: www.tikcro.com

38 Hanasi Weizmann
Hadera, 3842247
Israel
Phone: 972 4 671 5933


Officers

Name Title
Mr. Aviv Boim Chief Exec. Officer

Exchange: PINK

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.3691
Price-to-Sales TTM: 0
IPO Date:
Fiscal Year End: December
Full Time Employees: 0
Back to stocks